---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-027568"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T17:45:43.698147+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aquestive reports Q3 2022 revenue $11.5M, net loss $12.5M; licensing deals and AQST-109 progress

## Summary
- Total revenues $11.5M (down from $13.3M Q3 2021); net loss $12.5M ($0.23/share) vs $14.6M ($0.37) prior year.
- Cash $18.6M; reaffirms FY2022 revenue guidance $46-49M and adjusted EBITDA loss $37-43M.
- AQST-109 epinephrine film: positive EPIPHAST II data; FDA EoP2 meeting scheduled Q4 2022.
- Licensing deals: Pharmanovia (Libervant EU/UK/MENA) $3.5M upfront; Otter/Assertio (Sympazan) $9M upfront + $6M milestone; Haisco (Exservan China) $7M upfront.
- Appointed Dr. Kenneth Truitt as CMO; Timothy Morris to board; exploring out-licensing Libervant North America.

## SEC filing metadata
- accession: 0001628280-22-027568
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000162828022027568/0001628280-22-027568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000162828022027568/aqst-20221101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-027568
- JSON: https://secwatch.observer/filing/0001628280-22-027568.json
- Plain text: https://secwatch.observer/filing/0001628280-22-027568.txt

## Key facts
- Earnings Releases
  Aquestive Therapeutics, Inc. updated its third quarter ended September 30, 2022 guidance (reaffirmed).
  - Period: third quarter ended September 30, 2022
  - Guidance: reaffirmed
  - Result: reported results
  source text: On November 1, 2022, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the third quarter ended September 30, 2022 and provided an update on recent developments in its business.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1398733/000162828022027568/0001628280-22-027568-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.